Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LSTA 
Lisata Therapeutics Inc. (LSTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LSTA (1-star) is a SELL. SELL since 1 days. Profits (-18.97%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.67
1 Year Target Price $20.67
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.15% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.89M USD | Price to earnings Ratio - | 1Y Target Price 20.67 |
Price to earnings Ratio - | 1Y Target Price 20.67 | ||
Volume (30-day avg) 3 | Beta 0.94 | 52 Weeks Range 1.87 - 4.20 | Updated Date 08/29/2025 |
52 Weeks Range 1.87 - 4.20 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.64 | Actual -0.54 |
Profitability
Profit Margin - | Operating Margin (TTM) -6954.29% |
Management Effectiveness
Return on Assets (TTM) -38.76% | Return on Equity (TTM) -64.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1717221 | Price to Sales(TTM) 20.46 |
Enterprise Value -1717221 | Price to Sales(TTM) 20.46 | ||
Enterprise Value to Revenue 0.32 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 8598200 | Shares Floating 7259644 |
Shares Outstanding 8598200 | Shares Floating 7259644 | ||
Percent Insiders 19.82 | Percent Institutions 8.94 |
Upturn AI SWOT
Lisata Therapeutics Inc.
Company Overview
History and Background
Lisata Therapeutics, Inc. (formerly Cend Therapeutics) was founded to develop innovative cancer therapies. They focus on tumor microenvironment and targeted drug delivery.
Core Business Areas
- Drug Development: Developing and commercializing novel cancer therapies using their proprietary LSTA targeting technology.
Leadership and Structure
Executive leadership includes Dr. David Mazzo (CEO). The company has a board of directors and operates with defined clinical, research, and business development teams.
Top Products and Market Share
Key Offerings
- LSTA (Lisata Peptide): A novel tumor-targeting technology designed to enable selective delivery of anti-cancer therapies to the tumor microenvironment. Currently in clinical trials for various solid tumors. Competitors: Companies developing similar tumor targeting drug delivery platforms.
- NP-LSTA-paclitaxel: Novel formulation of paclitaxel designed to target solid tumors with LSTA, in phase 1 clinical trial for advanced solid tumors. Competitors: Traditional paclitaxel and other taxane-based chemotherapies.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by an aging population and advancements in cancer diagnostics and treatment. Targeted therapies are a key area of focus.
Positioning
Lisata Therapeutics Inc. is positioned as a developer of novel tumor-targeted therapies within the larger oncology market. Their LSTA technology aims to improve drug delivery and efficacy.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated in the hundreds of billions of dollars globally. Lisata aims to capture a portion of this market through improved targeted drug delivery. Specific TAM for their products depends on clinical trial outcomes.
Upturn SWOT Analysis
Strengths
- Novel LSTA tumor-targeting technology
- Potential for improved drug delivery and efficacy
- Experienced management team
Weaknesses
- Early stage clinical development
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Potential for regulatory hurdles
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of LSTA technology to other cancer types
- Positive clinical trial results
- Potential for orphan drug designation
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory delays
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- ONCR
Competitive Landscape
Lisata's advantage lies in its novel tumor-targeting technology. Disadvantages include its smaller size and earlier stage of development compared to established pharmaceutical companies. Key competitors are involved in targeted cancer therapies with clinical activity.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical and early clinical development. Future growth depends on clinical trial success and potential partnerships.
Future Projections: Future projections are speculative and dependent on clinical trial outcomes. Analyst estimates would be necessary for a specific forecast.
Recent Initiatives: Advancing clinical trials of LSTA-based therapies, seeking partnerships for further development and commercialization.
Summary
Lisata Therapeutics is a clinical-stage biotech company focused on tumor-targeted drug delivery. Their LSTA technology has potential, but the company faces risks associated with clinical trials and funding. Positive clinical data and strategic partnerships are crucial for future success. They need to carefully manage cash burn and navigate regulatory hurdles, but the tumor targeting technologies could be promising.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (general industry data)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be outdated or incomplete. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lisata Therapeutics Inc.
Exchange NASDAQ | Headquaters Basking Ridge, NJ, United States | ||
IPO Launch date 1999-03-01 | President, CEO & Director Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.lisata.com |
Full time employees 26 | Website https://www.lisata.com | ||
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.